Formosa Pharmaceuticals, Inc.
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007 that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resi… Read more
Formosa Pharmaceuticals, Inc. - Asset Resilience Ratio
Formosa Pharmaceuticals, Inc. (6838) has an Asset Resilience Ratio of 57.93% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Formosa Pharmaceuticals, Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Formosa Pharmaceuticals, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.22 Billion | 57.93% |
| Total Liquid Assets | NT$1.22 Billion | 57.93% |
Asset Resilience Insights
- Very High Liquidity: Formosa Pharmaceuticals, Inc. maintains exceptional liquid asset reserves at 57.93% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Formosa Pharmaceuticals, Inc. Industry Peers by Asset Resilience Ratio
Compare Formosa Pharmaceuticals, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Formosa Pharmaceuticals, Inc. (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Formosa Pharmaceuticals, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 57.76% | NT$1.22 Billion | NT$2.11 Billion | +9.61pp |
| 2023-12-31 | 48.15% | NT$831.41 Million | NT$1.73 Billion | +30.66pp |
| 2022-12-31 | 17.49% | NT$153.55 Million | NT$877.91 Million | -- |